IP Verse

Pfizer Inc. competitive analysis

Latest oppositions filed by Pfizer Inc.

Explore patent oppositions filed by Pfizer Inc. against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
EP4051265
Functionalized Peptides As Antiviral AgentsENANTA PHARMACEUTICALSMay 6, 2026
EP3527224
Rsv Immunization RegimenGLAXOSMITHKLINE BIOLOGICALS SANov 26, 2025
EP4144368
Rsv Immunization RegimenGLAXOSMITHKLINE BIOLOGICALS SANov 26, 2025
EP3595727
Lipid Nanoparticle FormulationMODERNAAug 26, 2025
EP4108671
Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses ThereofMODERNAAug 20, 2025
EP3981437
Nucleic Acid VaccinesMODERNAJul 4, 2025
EP4023249
Nucleic Acid VaccinesMODERNAJul 4, 2025
EP4032979
Factor Ix Polypeptide Mutant, Its Uses And A Method For Its ProductionUNIQURE BIOPHARMAJan 31, 2025
EP3638696
Use Of Anti Cd70 Antibody Argx-110 To Treat Acute Myeloid LeukaemiaARGENXDec 6, 2024
EP3596123
Fc-Optimized Anti-Cd25 For Tumour Specific Cell DepletionCANCER RESEARCH TECHNOLOGYOct 4, 2024

Latest patents of Pfizer Inc. opposed by its competitors

Explore Pfizer Inc.'s recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP4249069
Nov 19, 2025Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea1
EP3781132
Mar 20, 2024Apixaban Formulations1
EP3977993
Jan 31, 2024Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole For Use As A Medicament3
EP2768944
Nov 22, 2023Addition Of Iron To Improve Cell Culture2
EP3583947
Oct 11, 2023Streptococcus Pneumoniae Capsular Polysaccharides And Conjugates Thereof2
EP3555064
Mar 1, 2023Glp-1 Receptor Agonists And Uses Thereof1
EP3191461
Nov 3, 2021Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole6
EP3498734
Sep 1, 2021Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer7
EP3431475
Apr 7, 2021Solid Forms Of A Selective Cdk4/6 Inhibitor4
EP2968155
Mar 3, 2021Tofacitinib Oral Sustained Release Dosage Forms7

Latest PTAB cases involving Pfizer Inc.

Discover the latest PTAB cases involving Pfizer Inc., highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 26, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Pfizer Inc.

IPR2023-01358Aug 28, 2023PFIZERMODERNAFinal Written Decision - Appealed
IPR2023-01358Aug 28, 2023PFIZERMODERNATXFinal Written Decision - Appealed
IPR2021-01132Jun 17, 2021APOTEXPFIZERTerminated-Settled
IPR2021-00925May 11, 2021PFIZERUNIQURE BIOPHARMAFinal Written Decision
IPR2021-00926May 11, 2021PFIZERUNIQURE BIOPHARMAFinal Written Decision
IPR2021-00928May 11, 2021PFIZERUNIQURE BIOPHARMAFinal Written Decision
IPR2021-00528Feb 10, 2021PFIZERAMGENTerminated-Settled
IPR2021-00528Feb 10, 2021PFIZERSENCZUKTerminated-Settled
IPR2020-01252Jul 22, 2020PFIZERNOVO NORDISKTerminated-Settled
IPR2020-01252Jul 22, 2020PFIZERPEDERSENTerminated-Settled

Peer Comparison New

IP litigation analysis comparing Pfizer Inc. with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
PFIZER54994412
GENENTECH - 115 - 66
GLAXOSMITHKLINE BIOLOGICALS SA149329
MODERNA58012